<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Nephrol</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Nephrol</journal-id>
      <journal-title-group>
        <journal-title>BMC Nephrology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2369</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24708483</article-id>
      <article-id pub-id-type="pmc">4234137</article-id>
      <article-id pub-id-type="publisher-id">1471-2369-15-59</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2369-15-59</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Progressive multifocal cerebral infarction in a young kidney transplant recipient due to thrombotic microangiopathy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Haghikia</surname>
            <given-names>Arash</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>haghikia.arash@mh-hannover.de</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Heeren</surname>
            <given-names>Meike</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>heeren.meike@mh-hannover.de</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Bockmeyer</surname>
            <given-names>Clemens</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>bockmeyer.clemens@mh-hannover.de</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Haubitz</surname>
            <given-names>Bernd</given-names>
          </name>
          <xref ref-type="aff" rid="I5">5</xref>
          <email>haubitz.bernd@mh-hannover.de</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Gwinner</surname>
            <given-names>Wilfried</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I6">6</xref>
          <email>gwinner.wilfired@mh-hannover.de</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Center of Internal Medicine, Hannover Medical School, Hannover, Germany</aff>
      <aff id="I2"><label>2</label>Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany</aff>
      <aff id="I3"><label>3</label>Department of Neurology, Hannover Medical School, Hannover, Germany</aff>
      <aff id="I4"><label>4</label>Department of Pathology, Hannover Medical School, Hannover, Germany</aff>
      <aff id="I5"><label>5</label>Department of Neuroradiology, Hannover Medical School, Hannover, Germany</aff>
      <aff id="I6"><label>6</label>Department of Nephrology and Hypertensiology, Hannover Medical School, Hannover, Germany</aff>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>7</day>
        <month>4</month>
        <year>2014</year>
      </pub-date>
      <volume>15</volume>
      <fpage>59</fpage>
      <lpage>59</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>6</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>5</day>
          <month>3</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Haghikia et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>Haghikia et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2369/15/59"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Renal transplant recipients frequently experience neurological complications. Whereas ischemic stroke, cerebral haemorrhage or hypertensive encephalopathy often result from vascular alterations prior to transplantation, other cerebral diseases like CNS infections, primary brain tumors and drug induced neurotoxicity may develop as consequences of the required post-transplant immunosuppressive treatment.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>Here we report on an unusual clinical course of a young kidney transplant recipient with a cluster of fulminant necrotic brain lesions within a period of two months due to thrombotic microangiopathy.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Cerebral ischemia in organ transplant recipients should prompt one to consider thrombotic microangiopathy.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Cerebral infarctions</kwd>
        <kwd>Kidney transplantation</kwd>
        <kwd>Microangiopathy</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Neurological complications post transplantation include infections and tumours promoted by the immunosuppressive therapy in general and more frequently, tremor and peripheral neuropathies which are commonly related to the therapy with calcineurin inhibitors [<xref ref-type="bibr" rid="B1">1</xref>]. Severe calcineurin inhibitor-related side effects occur in 10% and are, mostly, reversible after dose reduction or cessation of the drug. These include decreased responsiveness, hallucinations, delusions, seizures, cortical blindness, and stroke-like episodes [<xref ref-type="bibr" rid="B2">2</xref>]. Rarely, calcineurin inhibitor related neurotoxicity presents as so-called &#x201C;reversible posterior leukoencephalopathy&#x201D; (RLPS) [<xref ref-type="bibr" rid="B3">3</xref>].</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 25-year-old male caucasian patient presented with a 1-week history of left-sided weakness, preceded by general fatigue and progressive forgetfulness in the previous two months. His medical history comprised a kidney transplantation 12&#xA0;years earlier for end-stage renal failure due to focal and segmental glomerulosclerosis, a longstanding well-controlled hypertension (RR 130/85&#xA0;mmHg in the previous months), mild pancytopenia with a previous diagnosis of a hypoplastic bone marrow with presumed toxic cause. At admission, his therapy included cyclosporine A 35&#xA0;mg b.i.d, prednisolone 7.5&#xA0;mg, valsartan 160&#xA0;mg b.i.d and 40&#xA0;&#x3BC;g darbepoetin alfa every two weeks. Arterial blood pressure at admission was 129/90&#xA0;mmHg and body temperature was normal. The strength of the left-sided limbs was mildly decreased (4+/5). Initially, leucocytopenia and mild thrombopenia, a haemoglobin concentration of 11&#xA0;g/dl and normal C-reactive protein were present (Table&#xA0;<xref ref-type="table" rid="T1">1</xref>). The serum creatinine concentration was 156&#xA0;&#x3BC;mol/l (equaling an eGFR of 47&#xA0;ml/min) which was in line with values of the preceding years. Actual and previous values for lactate dehydrogenase were normal (238 U/l).</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Depicts the course of some laboratory values</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Lab data</bold>
              </th>
              <th align="center">
                <bold>4 Weeks earlier</bold>
              </th>
              <th align="center">
                <bold>Admission</bold>
              </th>
              <th align="center">
                <bold>Shortly before death</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">Hemoglobin (g/dl)<hr/></td>
              <td align="center" valign="bottom">11<hr/></td>
              <td align="center" valign="bottom">11.1<hr/></td>
              <td align="center" valign="bottom">8.8<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">White blood cells (thousand/&#x3BC;l)<hr/></td>
              <td align="center" valign="bottom">3.9<hr/></td>
              <td align="center" valign="bottom">0.7<hr/></td>
              <td align="center" valign="bottom">4.0<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Platelets (thousand/&#x3BC;l)<hr/></td>
              <td align="center" valign="bottom">168<hr/></td>
              <td align="center" valign="bottom">265<hr/></td>
              <td align="center" valign="bottom">15<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Creatinine (&#x3BC;mol/l)<hr/></td>
              <td align="center" valign="bottom">156<hr/></td>
              <td align="center" valign="bottom">161<hr/></td>
              <td align="center" valign="bottom">124<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CRP (mg/l)<hr/></td>
              <td align="center" valign="bottom">6<hr/></td>
              <td align="center" valign="bottom">4<hr/></td>
              <td align="center" valign="bottom">4<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">LDH (U/l)<hr/></td>
              <td align="center" valign="bottom">238<hr/></td>
              <td align="center" valign="bottom">198<hr/></td>
              <td align="center" valign="bottom">601<hr/></td>
            </tr>
            <tr>
              <td align="left">Cyclosporin A level (&#x3BC;g/l).</td>
              <td align="center">64</td>
              <td align="center">&lt; 15</td>
              <td align="center">&lt;15</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>A cranial MRI showed right-sided temporo-parietal and thalamic lesions (Figure<xref ref-type="fig" rid="F1">1</xref>A). Correspondingly, MR angiography revealed a missing flow signal of the right middle cerebral artery (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>B). Cardiac thromboembolism was excluded by transesophageal echocardiography. By Doppler ultrasonography and MR angiography, arterial occlusive disease, vasculitis and aneurysms of the extracranial brain-supplying arteries and of the aorta were excluded. Vasculitits was further excluded by negative results for anti-nuclear antibodies, ANCA, anti-mitochondrial antibodies, anti-cardiolipin antibodies, cryoglobulins/HCV and HIV status. Acetyl salicylic acid was prescribed and the patient was discharged.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Cranial MR Imaging of the cerebral lesions. (A)</bold> Initial cranial MRI demonstrating right-sided temporo-parietal and thalamic lesions of different age. <bold>(B)</bold> MR angiography depicting missing flow signal of the right middle cerebral artery.</p>
        </caption>
        <graphic xlink:href="1471-2369-15-59-1"/>
      </fig>
      <p>Four weeks later he was admitted again because of listlessness and mutism. At this admission leucopenia had progressed to 0.7 thousand/&#x3BC;l, the haemoglobin concentration was 11.1&#xA0;g/dl and the thrombocyte count 200 thousand/&#x3BC;l. The serum creatinine concentration was 161&#xA0;&#x3BC;mol/l and the cyclosporine A trough level (measured by mass spectrometry; LC-MS/MS) was below the detection limit (15&#xA0;&#x3BC;g/l) (Table&#xA0;<xref ref-type="table" rid="T1">1</xref>). A bone marrow examination revealed hypoplasia with dysmature haematopoiesis. An electroencephalogram displayed left-sided fronto-temporal intermittent rhythmic delta-activity without epileptiform discharges. The cerebrospinal fluid (CSF) was normal including virology (CMV, HSV, VZV, EBV, enterovirus and JCV). Moreover, repeatedly negative results of CRP and normal body temperature argued against an infection.</p>
      <p>At the 5<sup>th</sup> day, he was discovered having bilateral blindness accompanied by moderate to severe loss of conscious (Glascow coma scale of 8) within the next two days. At the onset of these symptoms cyclosporine A was paused. A follow-up cranial MRI revealed new ischemic lesions of the left-sided thalamus and both occipital regions. Brain biopsy was decided and the histology showed extensive necrosis and arteriolar hyalinosis. No findings of vasculitis, inflammatory, infectious (negative tests for CMV, HSV, VZV, EBV and JCV) or neoplastic processes were detected. In the next two days the patient increasingly developed severe hypertension with systolic values above 220&#xA0;mmHg. Three days after the brain biopsy thrombocyte count rapidly declined to 25 thousand/&#x3BC;l. Schistocytes remained negative and ADAMTS-13 activity and C3c, C4 and CH50 complement titers were normal but lactate dehydrogenase increased to 550 U/l. A cranial CT-scan (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>) demonstrated bilateral infarct lesions in the posterior circulation territory. The patient was transferred for anti-hypertensive treatment to the ICU, where he died after developing further cerebral infarctions of the brain stem. Post-mortem examination revealed disseminated thrombotic microangiopathy in the brain, the lungs and the renal allograft (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>).</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>A cranial CT-scan at a later stage of disease demonstrated additional bilateral infarct lesions in the posterior circulation territory.</p>
        </caption>
        <graphic xlink:href="1471-2369-15-59-2"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p><bold>Postmortem diagnosis of thrombotic microangiopathy.</bold> Intravascular thrombi are indicated by arrows. <bold>A</bold>: pre-glomerular arteriole of the transplanted kidney; <bold>B</bold>: arteriole in the brain tissue; and thombi in a smaller <bold>(C)</bold> and in a larger arterial <bold>(D)</bold> vessel of the lung. PAS staining <bold>(A, B)</bold>, HE staining <bold>(C, D)</bold>, magnification x400.</p>
        </caption>
        <graphic xlink:href="1471-2369-15-59-3"/>
      </fig>
    </sec>
    <sec>
      <title>Conclusions and consent</title>
      <p>The prevalence of acute cerebral ischemia among renal transplant recipients has been estimated at 8% [<xref ref-type="bibr" rid="B4">4</xref>]. Arteriosclerotic vascular disease or hypertensive encephalopathy was unlikely causative in this young patient because of the absence of relevant risk factors. Also, arterial thromboembolism was definitely ruled out. CNS infection which comprise about 40% of all cerebral complications and are mostly seen during the first 24&#xA0;months post transplantation [<xref ref-type="bibr" rid="B5">5</xref>], was not evident in our patient Although calcineurin inhibitors have emerged as a frequent cause of neurologic symptoms and disease, affecting 25% to 59% of transplant patients, gross infarction is typically not seen with these compounds [<xref ref-type="bibr" rid="B2">2</xref>]. In our patient, previous cyclosporine trough levels were consistently very low and no clinical improvement was achieved after stopping cyclosporine A treatment. Nevertheless, this does not completely argue against cyclosporine A-induced vascular injury because high calcineurin-inhibitor levels appear to be not a pre-requisite and cessation of the drug in our patient may have been too late to change the course of disease.</p>
      <p>Another complication which may be attributed to cyclosporine A is thrombotic microangiopathy (TMA) [<xref ref-type="bibr" rid="B6">6</xref>]. A study by Zarifian et al. reviewing 188 patients reported TMA as the cause of renal graft dysfunction in 14% of renal graft recipients and 92% of the TMA cases were on therapy with cyclosporine A [<xref ref-type="bibr" rid="B7">7</xref>]. Noteworthy, conversion from cyclosporine A to tacrolimus resulted in salvage of graft function in 81% of the cases. Onset of TMA was highly variable with 4&#xA0;days to 2190&#xA0;days post-transplantation, suggesting that other precipitating factors besides cyclosporine A may have been present in some patients. In none of the patients, extrarenal involvement of TMA was reported. In our case, postmortal histopathological examination clearly showed signs of TMA in the brain, in the lungs and in the renal transplant. Early recognition of TMA in our patient was impeded as the initial biopsy did not report TMA as the cause of brain necrosis, mild pancytopenia was pre-existing and clear signs of thrombotic microangiopathy with hemolysis were missing until major cerebral damage had occurred. Also, in our patient there was no clue for TMA in the former history with regard to his original renal disease, in an allograft biopsy performed two years before his death, or in his family. As diarrhoea was not present at any time we did not include infectious haemolytic uremic syndrome in our differential diagnosis. Unfortunately, we could not perform thorough complement gene analysis in this short disease course to establish whether atypical haemolytic uremic syndrome was causative for the TMA. Nevertheless, C3c, C4 and CH50 complement titers were normal at the time of presentation.</p>
      <p>This case emphasizes that TMA can take a smouldering course in transplant patients without typical signs like severe thrombopenia or the characteristic picture of haemolytic-uremic syndrome with severe anemia and renal dysfunction. Earlier intervention may have had changed the course in our patient. Although there is no proof that cyclosporine A was causative, prompt withdrawal may have been beneficial. Plasmapheresis has been the mainstay in the treatment of TMA. Improved allograft outcomes have been reported particularly with pre-emptive plasmapheresis therapy in patients with known risk for atypical haemolytic uremic syndrome [<xref ref-type="bibr" rid="B8">8</xref>]. More recently, eculizumab has emerged as an efficacious therapy in such patients, either with or without plasmapheresis treatment [<xref ref-type="bibr" rid="B9">9</xref>]. Yet, at the point where TMA with a possible underlying diagnosis of atypical haemolytic uremic syndrome had to be considered in our patient, the cerebral infarction was advanced excluding a relevant improvement by this therapy.</p>
      <p>Written informed consent was from the parents of the patient for the publication of this report and any accompanying images.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>AH and WG were involved in the treatment of the patient and acquisition, analysis and interpretation of the medical history of the patient, drafting the manuscript and have given final approval of the version to be published. MH, BH and CB were involved in the diagnostic procedures, interpretation and discussing the results, and in critically revising the manuscript for important intellectual content. All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2369/15/59/prepub">http://www.biomedcentral.com/1471-2369/15/59/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Funding</title>
      <p>Intramural.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ponticelli</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Campise</surname>
            <given-names>MR</given-names>
          </name>
          <article-title>Neurological complications in kidney transplant recipients</article-title>
          <source>J Nephrol</source>
          <year>2005</year>
          <volume>18</volume>
          <fpage>521</fpage>
          <lpage>528</lpage>
          <pub-id pub-id-type="pmid">16299677</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gijtenbeek</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>van den Bent</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Vecht</surname>
            <given-names>CJ</given-names>
          </name>
          <article-title>Cyclosporine neurotoxicity: a review</article-title>
          <source>J Neurol</source>
          <year>1999</year>
          <volume>246</volume>
          <fpage>339</fpage>
          <lpage>346</lpage>
          <pub-id pub-id-type="doi">10.1007/s004150050360</pub-id>
          <pub-id pub-id-type="pmid">10399863</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lee</surname>
            <given-names>VH</given-names>
          </name>
          <name>
            <surname>Wijdicks</surname>
            <given-names>EF</given-names>
          </name>
          <name>
            <surname>Manno</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Rabinstein</surname>
            <given-names>AA</given-names>
          </name>
          <article-title>Clinical spectrum of reversible posterior leukoencephalopathy syndrome</article-title>
          <source>Arch Neurol</source>
          <year>2008</year>
          <volume>65</volume>
          <fpage>205</fpage>
          <lpage>210</lpage>
          <pub-id pub-id-type="pmid">18268188</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Oliveras</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Roquer</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Puig</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Rodr&#xED;guez</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mir</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Orfila</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Masramon</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lloveras</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Stroke in renal transplant recipients: epidemiology, predictive risk factors and outcome</article-title>
          <source>Clin Transplant</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>1</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1034/j.1399-0012.2003.02042.x</pub-id>
          <pub-id pub-id-type="pmid">12588314</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sakhuja</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Sud</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kalra</surname>
            <given-names>OP</given-names>
          </name>
          <name>
            <surname>D&#x2019;Cruz</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kohli</surname>
            <given-names>HS</given-names>
          </name>
          <name>
            <surname>Jha</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Gupta</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Vasishta</surname>
            <given-names>RK</given-names>
          </name>
          <article-title>Central nervous system complications in renal transplant recipients in a tropical environment</article-title>
          <source>J Neurol Sci</source>
          <year>2001</year>
          <volume>183</volume>
          <fpage>89</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.1016/S0022-510X(00)00485-8</pub-id>
          <pub-id pub-id-type="pmid">11166801</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Satoskara</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Pelletierb</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Adamsb</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Nadasdya</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Brodskya</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Pesaventoc</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Henryb</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Nadasdya</surname>
            <given-names>T</given-names>
          </name>
          <article-title>De novo thrombotic microangiopathy in renal allograft biopsies&#x2014;role of antibody-mediated rejection</article-title>
          <source>Am J Transplant</source>
          <year>2010</year>
          <volume>10</volume>
          <fpage>1804</fpage>
          <lpage>1811</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-6143.2010.03178.x</pub-id>
          <pub-id pub-id-type="pmid">20659088</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Zarifian</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Meleg-Smith</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>O&#x2019;donovan</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Tesi</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Batuman</surname>
            <given-names>V</given-names>
          </name>
          <article-title>Cyclosporine- associated thrombotic microangiopathy in renal allografts</article-title>
          <source>Kidney Int</source>
          <year>1999</year>
          <volume>55</volume>
          <fpage>2457</fpage>
          <lpage>2466</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1523-1755.1999.00492.x</pub-id>
          <pub-id pub-id-type="pmid">10354295</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Le Quintreca</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zuberc</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Moulind</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Kamare</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Jablonskic</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lionetg</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Chateleth</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Moussoni</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Mouradj</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bridouxk</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Cassutol</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Loiratm</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rondeaun</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Delahoussea</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Fre&#x2019;meaux-Bacchio</surname>
            <given-names>V</given-names>
          </name>
          <article-title>Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome</article-title>
          <source>Am J Transplant</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>663</fpage>
          <lpage>675</lpage>
          <pub-id pub-id-type="doi">10.1111/ajt.12077</pub-id>
          <pub-id pub-id-type="pmid">23356914</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Zubera</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Le Quintrecb</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kridc</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bertoyed</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Gueutine</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Lahochef</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Heyneg</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Ardissinoh</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Chateleti</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>L&#x2013;H</surname>
            <given-names>N l</given-names>
          </name>
          <name>
            <surname>Hourmantj</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Niaudetc</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Fre&#x2019;meaux-Bacchik</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Rondeaul</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Legendrea</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Loiratm</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation</article-title>
          <source>Am J Transplant</source>
          <year>2012</year>
          <volume>12</volume>
          <fpage>3337</fpage>
          <lpage>3354</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-6143.2012.04252.x</pub-id>
          <pub-id pub-id-type="pmid">22958221</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
